Solid Biosciences (NASDAQ:SLDB) COO David Howton Sells 18,894 Shares of Stock

Solid Biosciences Inc. (NASDAQ:SLDB) COO David Howton sold 18,894 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total transaction of $121,677.36. Following the completion of the sale, the chief operating officer directly owned 97,859 shares of the company’s stock, valued at $630,211.96. This represents a 16.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Solid Biosciences Trading Up 4.7%

Shares of Solid Biosciences stock opened at $6.52 on Friday. The company has a market cap of $507.97 million, a PE ratio of -2.62 and a beta of 2.67. The company has a 50 day moving average of $5.84 and a 200-day moving average of $5.72. Solid Biosciences Inc. has a 1-year low of $2.41 and a 1-year high of $7.37.

More Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Company will present at the Guggenheim Emerging Outlook: Biotech Summit (CEO Bo Cumbo presenting Feb 12) — this gives Solid (SLDB) direct exposure to institutional investors and can support a rally if management provides encouraging clinical, regulatory, or financing updates. Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
• Neutral Sentiment: Trading context: SLDB is trading above recent moving averages with volume notably above its average — this suggests heightened interest but does not by itself indicate direction until drivers (presentation vs. insider sales) dominate.
• Negative Sentiment: CEO Alexander (Alex) Cumbo sold 48,913 shares at an average $6.44 (≈$315k); his holding fell ~18.1% — a large CEO sale can be read negatively by investors even if for personal reasons. CEO Sale SEC Filing
• Negative Sentiment: CFO Kevin Tan sold 14,783 shares at $6.44 (~$95k); his position fell ~13.6% — another senior officer reduction that may weigh on sentiment. CFO Sale SEC Filing
• Negative Sentiment: COO David T. Howton sold 18,894 shares at $6.44 (~$122k); ownership declined ~16.2%. COO Sale SEC Filing
• Negative Sentiment: CTO Paul Herzich sold 10,905 shares at $6.44 (~$70k); holding fell ~13.6%. CTO Sale SEC Filing
• Negative Sentiment: Other insiders — director Ilan Ganot (7,205 shares), insider Jessie Hanrahan (12,348 shares), and Gabriel Brooks (12,616 shares) — each sold at $6.44, reducing holdings by double-digit percentages; collectively these sales increase supply pressure and raise investor questions about insider confidence. Director/Insider Sales SEC Filings

Analysts Set New Price Targets

A number of brokerages have issued reports on SLDB. Citigroup reissued a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Wall Street Zen lowered Solid Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a report on Thursday, January 22nd. Barclays set a $9.00 price objective on shares of Solid Biosciences and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $15.00 target price on shares of Solid Biosciences in a report on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.70.

Institutional Trading of Solid Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc lifted its stake in shares of Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after purchasing an additional 4,063 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after buying an additional 4,534 shares in the last quarter. Creative Planning purchased a new stake in Solid Biosciences during the second quarter worth approximately $57,000. Russell Investments Group Ltd. increased its position in shares of Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after acquiring an additional 5,991 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in shares of Solid Biosciences by 233.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock valued at $74,000 after acquiring an additional 10,585 shares during the period. 81.46% of the stock is currently owned by hedge funds and other institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.